rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2005-2-23
|
pubmed:abstractText |
The aim of this study was to define the recommended dose of oxaliplatin when combined with infusional 5-fluorouracil (5-FU) and concurrent pelvic radiotherapy. Eligible patients had inoperable rectal cancer, or symptomatic primary rectal cancer with metastasis. Oxaliplatin was given on day 1 of weeks 1, 3 and 5 of radiotherapy. Dose level 1 was oxaliplatin 70 mg m(-2) with 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1). On dose level 2, the oxaliplatin dose was increased to 85 mg m(-2). On dose level 3, the duration of the 5-FU was increased to 168 h per week. Pelvic radiotherapy was 45 Gray (Gy) in 25 fractions over 5 weeks with a boost of 5.4 Gy. Fluorine-18 fluoro deoxyglucose and Fluorine-18 fluoro misonidazole positron emission tomography (FDG-PET and FMISO-PET) were used to assess metabolic tumour response and hypoxia. In all, 16 patients were accrued. Dose-limiting toxicities occurred in one patient at level 2 (grade 3 chest infection), and two patients at level 3 (grade 3 diarrhoea). Dose level 2 was declared the recommended dose level. FDG-PET imaging showed metabolic responses in 11 of the 12 primary tumours assessed. Four of six tumours had detectable hypoxia on FMISO-PET scans. The addition of oxaliplatin to infusional 5-FU chemoradiotherapy was feasible and generally well tolerated. For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10421535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10561302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10673991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10944126,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10944647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-11134203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-11331322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12243813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12416580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12663716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12915600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-14665611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-15496622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-1997835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-2405793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-6534106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8041415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8079744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8133857,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8661826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8961365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-9091798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-9278661
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0007-0920
|
pubmed:author |
pubmed-author:HicksR JRJ,
pubmed-author:LeoniJJ,
pubmed-author:Lim-JoonDD,
pubmed-author:LowAA,
pubmed-author:MackayJJ,
pubmed-author:MichaelMM,
pubmed-author:MitchellPP,
pubmed-author:MukeshBB,
pubmed-author:NganS Y KSY,
pubmed-author:RischinDD,
pubmed-author:ZalcbergJJ
|
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
655-61
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15700033-Adult,
pubmed-meshheading:15700033-Aged,
pubmed-meshheading:15700033-Aged, 80 and over,
pubmed-meshheading:15700033-Antimetabolites, Antineoplastic,
pubmed-meshheading:15700033-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15700033-Chemotherapy, Adjuvant,
pubmed-meshheading:15700033-Drug Administration Schedule,
pubmed-meshheading:15700033-Female,
pubmed-meshheading:15700033-Fluorodeoxyglucose F18,
pubmed-meshheading:15700033-Fluorouracil,
pubmed-meshheading:15700033-Humans,
pubmed-meshheading:15700033-Infusions, Intravenous,
pubmed-meshheading:15700033-Male,
pubmed-meshheading:15700033-Middle Aged,
pubmed-meshheading:15700033-Misonidazole,
pubmed-meshheading:15700033-Neoplasm Staging,
pubmed-meshheading:15700033-Organoplatinum Compounds,
pubmed-meshheading:15700033-Positron-Emission Tomography,
pubmed-meshheading:15700033-Radiopharmaceuticals,
pubmed-meshheading:15700033-Radiotherapy, Adjuvant,
pubmed-meshheading:15700033-Radiotherapy Dosage,
pubmed-meshheading:15700033-Rectal Neoplasms,
pubmed-meshheading:15700033-Treatment Outcome
|
pubmed:year |
2005
|
pubmed:articleTitle |
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
|
pubmed:affiliation |
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A'Beckett Street, Melbourne, Victoria 8006, Australia.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|